Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma-Reference-Cited by-同舟云学术

Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma

Published:2018-08-03 Issue:10 Volume:67 Page:1647-1658
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Albertini Mark R.,Yang Richard K.,Ranheim Erik A.,Hank Jacquelyn A.,Zuleger Cindy L.,Weber Sharon,Neuman Heather,Hartig Greg,Weigel Tracey,Mahvi David,Henry Mary Beth,Quale Renae,McFarland Thomas,Gan Jacek,Carmichael Lakeesha,Kim KyungMann,Loibner Hans,Gillies Stephen D.,Sondel Paul M.

Funder

National Cancer Institute

National Center for Advancing Translational Sciences

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2223-z/fulltext.html

Reference26 articles.

1. Albertini MR, Ranheim EA, Hank JA, Zuleger CL, McFarland T, Collins J et al (2014) A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma. Annual Meeting of the American Society of Clinical Oncology (ASCO 2014), Chicago, IL, USA, May 30-June 3, 2014. J Clin Oncol 32 (5 s): (Abstract 9044, Poster)

2. Albertini MR, Ranheim EA, Hank JA, Zuleger CL, McFarland T, Collins J et al (2016) Final statistical analysis of a pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016), National Harbor, MD, USA, November 9–13, 2016. J Immunother Cancer 4 (Suppl 1): (Abstract 163, Poster). https://doi.org/10.1186/s40425-016-0172-7